• 1
    American Joint Committee on Cancer. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lippincott, 1997.
  • 2
    Harris JR. Staging of breast carcinoma. In: HarrisJR, LippmanME, MorrowM, WellmanS, eds. Diseases of the Breast. New York: Lippincott-Raven, 1996 pp. 4579.
  • 3
    Turner RR, Ollila DW, Krasne DL, Giuliano AL. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997; 226: 2716.
  • 4
    Leers MPG, Schoffelen RHMG, Hoop JGM et al . Multiparameter flow cytometry as a tool for the detection of micrometastatic tumour cells in the sentinel lymph node procedure of patients with breast cancer. Clin Path 2002; 55: 35966.
  • 5
    Pargaonkar AS, Beissner RS, Snyder S, Speights VO. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch Pathol Lab Med 2003; 127: 7015.
  • 6
    Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80: 118897.
  • 7
    Alam SM, Clark JS, George WD, Campbell AM. Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunol Lett 1993; 35: 22934.
  • 8
    Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992; 12: 112.
  • 9
    Deutsch M, Deutsch A, Shirihai O et al . A novel miniature cell retainer for correlative high-content analysis of individual untethered non-adherent cells. Laboratory Chip 2006; 6: 9951000.
  • 10
    Deutsch A, Zurgil N, Hurevich I et al . Microplate cell-retaining methodology for high-content analysis of individual non-adherent unanchored cells in a population. Biomed Microdev 2006; 8: 36174.
  • 11
    Deutsch M, Kaufman M, Shapiro H, Zurgil N. Analysis of enzyme kinetics in individual living cells utilizing fluorescence intensity and polarization measurements. Cytometry 2000; 39: 3644.
  • 12
    Zurgil N, Sunray M, Shafran Y, Afrimzon E, Deutsch M. A novel approach for on line monitoring of apoptotic cell shrinkage in individual live lymphocytes. J Immunol Meth 2003; 281: 3749.
  • 13
    Afrimzon E, Zurgil N, Shafran Y et al . Monitoring of intracellular enzyme kinetic characteristics of peripheral mononuclear cells in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2004; 13: 23541.
  • 14
    Sameni M, Dosescu J, Sloane BF. Imaging proteolysis by living human glioma cells. Biol Chem 2001; 382: 7858.
  • 15
    Sameni M, Moin K, Sloarne BF. Imaging proteolysis by living human breast cancer cells. Neoplasia 2000; 2: 496504.
  • 16
    Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. Bioassays 2005; 27: 118191.
  • 17
    Afrimzon E, Deutsch A, Shafran Y et al . Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes. Clin Exp Metastasis 2008 ; Jan. 16 [Epub ahead of print.].
  • 18
    Veronesi U, Paganelli G, Viale G et al . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 54653.
  • 19
    Scoggins CR, Chagpar AB, Martin RCG, McMasters KM. Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? Nat Clin Pract Oncol 2005; 2: 44855.
  • 20
    Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003; 83: 33776.
  • 21
    Qian CN, Berghuis B, Tsarfaty G et al . Preparing the ‘Soil’: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 2006; 66: 10 36576.
  • 22
    Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett 2006; 238: 18896.
  • 23
    Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005; 2: e284.
  • 24
    Knutson KL, Krco CJ, Erskine CL et al . T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006; 24: 425461.
  • 25
    Copier J, Ward S, Dalgleish A. Cell based cancer vaccines: regulatory and commercial development. Vaccine 2007; 25 (Suppl 2): B3546.
  • 26
    Ullman KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990; 8: 42152.
  • 27
    Beverley PC. Activation antigens: new and previously defined clusters. In: McMichaelAJ, ed. Leucocyte Typing III. Oxford: Oxford University Press, 1987; 51628.
  • 28
    Barrett AJ, Rezvani K, Solomon S et al . New developments in allotransplant immunology. In: Hematology American Society of Hematology Education Program Book. San Francisco: The American Society of Hematology, 2003, 1, pp. 35071.
  • 29
    Abraham M, Shapiro S, Karni A, Weiner HL, Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs Th2 cells. J Neuroimmunol 2005; 163: 15764.
  • 30
    Melamed D, Messika O, Glass-Marmor L, Miller A. Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. Int Immunol 2006; 18: 135562.
  • 31
    Trocme C, Gaudin P, Berthier S, Barro C, Zaoui P, Morel F. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J Biol Chem 1998; 273: 20 67784.
  • 32
    Di Girolamo N, Tedla N, Lloyd A, Wakefield D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur J Immunol 1998; 28: 177384.
  • 33
    Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001; 61: 3493500.
  • 34
    Li HC, Cao DC, Liu Y et al . Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004; 88: 7585.